Combining high-dose irradiation of the primary tumor, low-dose radiation therapy of metastatic lesions, and immune checkpoint inhibitors in a mouse lung cancer model can effectively control metastatic tumors through immune response and downregulation of immunosuppressive factor TGF-β (Barsoumian et al. 2020). This evidence concerns the gene TGFB1 and neoplasm.